FULVESTRANT
Primitive Neuroectodermal Tumor
St. Jude Children's Research HospitalSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Primitive Neuroectodermal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
FILGRASTIM St. Jude Children's Research Hospital | Phase 1 | CCC |
LEUPROLIDE St. Jude Children's Research Hospital | Phase 1 | CC |
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
Zoladex St. Jude Children's Research Hospital | Phase 1 | CC |
View all 9 →
Same molecule, other indications
FULVESTRANT is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →